Embecta

Embecta Capital Intensity

The Capital Intensity Ratio of Embecta (EMBC) as of Nov 21, 2026 is 100.97 %. In the previous year, Capital Intensity Ratio was 114.44 % — a change of -11.77% (lower).

Capital Intensity

100.97 %

YoY

-11.77%

Last updated:

Capital Intensity Ratio of Embecta is 2025 100.97 % . Capital Intensity Ratio of Embecta was 2024 114.44 % . It decreases by -11.77% lower compared to the previous year.

The Embecta Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2019
67.18 USD
Jan 1, 2020
67.99 USD
Jan 1, 2021
67.64 USD
Jan 1, 2022
96.18 USD
Jan 1, 2023
108.35 USD
Jan 1, 2024
114.44 USD
Jan 1, 2025
100.97 USD
The Embecta Capital Intensity history
YEARCapital IntensityYoY
100.97 %-11.77%
114.44 %+5.62%
108.35 %+12.65%
96.18 %+42.20%
67.64 %-0.51%
67.99 %+1.20%
67.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Capital Intensity Ratio of Embecta is 100.97 % in 2025.

Capital Intensity Ratio of Embecta changed from 114.44 % to 100.97 %, representing a -11.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Embecta since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Embecta with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Embecta

All Key Metrics — Embecta